PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 114 results · Diabetes  · Clear
🔒 Subscribers only
AUTH/2906/11/16
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk
A CMRO paper (ABPI-funded) assessed whether results of company-sponsored trials for EMA-approved 2013 medicines were disclosed within 12 months of the later of first regulatory approval or trial co…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2890/11/16
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk websites
A health professional complained about Novo Nordisk’s UK corporate website and a separate professional resource website.Concerns included: patients shown with photos and full names; diabetes pati…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2887/11/16
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca
An anonymous, contactable complainant (described themself as a GP) complained about two AstraZeneca promotional meetings (November 2015 and November 2016) for Forxiga (dapagliflozin).The complainan…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2903/11/16
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk
The PMCPA Director initiated a complaint after a CMRO publication (25 Nov 2016) assessed disclosure of results for company-sponsored trials linked to new medicines approved by EMA in 2013.The publi…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2825/3/16
Off-label Promotion Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen v Boehringer Ingelheim & Lilly
Janssen-Cilag complained about a two-sided A4 “Dear UK Healthcare Professional” letter (ref UK/EMP/00241) about Jardiance (empagliflozin) cardiovascular outcomes.The letter was stapled to a rep…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2896/11/16
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen
A complaint was considered under case AUTH/2896/11/16.The case related to clinical trial disclosure for Invokana.The complainant was the Director (PMCPA).Company: Janssen.
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2907/11/16
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Takeda
A matter was considered by the PMCPA involving the Director and Takeda.The case related to clinical trial disclosure for Vipidia.Complaint received: 06 December 2016.
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2835/4/16
Off-label Promotion Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen voluntary admission over outdated Invokana prescribing information email (No breach)
Janssen-Cilag’s mailing agency inadvertently sent general practitioners a previously withdrawn promotional email for Invokana (canagliflozin) (ref PHGB/VOK/1015/0078) containing outdated prescrib…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2855/7/16
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Boehringer Ingelheim and Lilly
A pharmacist complained about a promotional email (Ref UK/GLA/00177) sent (5 July 2016) to a nurse in an NHS clinical commissioning group (CCG).The email subject line stated: “Biosimilar insulin …
Clauses: 9.1
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2851/6/16
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk
An anonymous, contactable complainant alleged Tresiba (insulin degludec) was promoted to the public via a LinkedIn posting.The LinkedIn communication named a Novo Nordisk employee and included cont…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2836/4/16
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AUTH/2836/4/16 AstraZeneca v Janssen
AstraZeneca UK complained about Janssen-Cilag promotional materials for Invokana (canagliflozin): two leavepieces (Oct 2015 PHGB/VOK/0815/0020; Jan 2016 PHGB/VOK/0815/0020(1)) and a journal adverti…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2915/12/16
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen
An anonymous, non-contactable complainant (self-described health professional) complained about the venue for a forthcoming promotional meeting for Invokana (canagliflozin) in type 2 diabetes.The i…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2913/12/16
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen
An anonymous, non-contactable complainant alleged a Janssen medical science liaison (MSL) approached a health professional at a UK primary care conference and asked how they wanted to receive infor…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2732/9/14
Social Media & Digital Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen
Janssen sent a ‘Dear Doctor’ letter about Invokana (canagliflozin) to GPs across 150 clinical commissioning groups (CCGs).The letter headline and opening stated Invokana had been approved by th…
Clauses: 9.1,9.2
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2715/5/14
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Lilly
An anonymous, non-contactable practice pharmacist complained about Lilly’s Enhanced Management of Type 2 Diabetes (EMD) nurse education/mentorship programme delivered in GP practices by an indepe…
Clauses: NONE
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2699/2/14
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
MSD MIRROR tool briefing materials
An anonymous, non-contactable clinician (with a CCG advisory role) complained about a meeting with two Merck Sharp & Dohme (MSD) representatives using a computer programme called MIRROR (an int…
Clauses: NONE
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2695/1/14
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi
A member of the public made a complaint to the PMCPA about clinical trial disclosure relating to Lyxumia.The matter was reviewed under the ABPI Code of Practice (applicable Code year: 2012).
Clauses: NONE
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2581/2/13
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
MSD’s Januvia leavepiece
Boehringer Ingelheim and Eli Lilly complained about a Merck Sharp & Dohme (MSD) promotional leavepiece for Januvia (sitagliptin) (ref DIAB-1061227), used as a linagliptin rebuttal/objection-han…
Clauses: NONE
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2637/9/13
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi Lyxumia “Speaker Club” invite
A consultant physician complained about an email invitation from Sanofi to attend a “Lyxumia Speaker Club”.The email offered an opportunity to discuss key Lyxumia data with a lead investigator,…
Clauses: NONE
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2619/7/13
Social Media & Digital Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi breached an undertaking by leaving Lyxumia “cost-effective/value” press release live (AUTH/26
Novo Nordisk complained that a Lyxumia (lixisenatide) press release on Sanofi’s website breached an undertaking Sanofi had given in an earlier case (AUTH/2604/5/13).The press release headline sta…
Clauses: 2
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2620/7/13
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi breached an undertaking over a repeat “only once-daily GLP‑1RA” claim in a Nursing Times supp
Novo Nordisk alleged that a claim for Lyxumia (lixisenatide) in a Nursing Times promotional supplement breached an undertaking Sanofi had given in an earlier case (AUTH/2604/5/13).The supplement (p…
Clauses: 2
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2520/6/12
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
GP complaint about alleged
A general practitioner complained that a jointly sponsored educational meeting on renal clinic referrals and kidney health was disguised promotion of Trajenta (linagliptin), co-promoted by Boehring…
Clauses: NONE
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2479/2/12
HCP Hospitality & Meetings Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk v Bristol-Myers Squibb & AstraZeneca
Novo Nordisk complained about a jointly sponsored satellite symposium at the Primary Care Diabetes Society (PCDS) conference (November 2011) titled “The Kidney in Type 2 Diabetes: Victim or Targe…
Clauses: NONE
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2477/2/12
HCP Hospitality & Meetings Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi
A consultant physician complained about a Sanofi representative’s conduct at a hospital diabetes centre meeting (25 January 2012).The representative discussed comparative data from the (then unpu…
Clauses: 12.1,14.1
2012 🔒 Subscribe
← Prev 1 2 3 4 5 Next → Page 3 of 5 — 114 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews